sGC 1061
Alternative Names: Nitric oxide mimetic (sGC-1061); nomethiazole sustained release; Nomethiazoles (NO-chimera prodrugs) - sGC Pharma; sGC-1061; Sustained-release sGC-1061Latest Information Update: 21 Mar 2023
At a glance
- Originator Queens University; University of Illinois
- Developer sGC Pharma
- Class Antidementias; Thiazoles
- Mechanism of Action Amyloid beta-protein inhibitors; Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 21 Mar 2023 Discontinued - Preclinical for Alzheimer's disease in USA (unspecified route)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Alzheimer's-disease in USA
- 28 Jul 2018 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (Controlled release)